Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
CME Credit Available: Maximum of 6 AMA PRA Category 1 Credits™
Release Date: March 26, 2007
Expiration Date: March 26, 2008
This activity consists of audio and visual recording of 8 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.
To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.
Needs and Objectives
Upon completion of this activity, learners will be able to:
- Design antiretroviral strategies that consider current data for:
- Managing complicated failure
- Interpreting resistance test results
- The role of investigational antiretroviral drugs
- Dyslipidemia and insulin resistance as metabolic toxicities of HIV and its therapies
- Discuss new data on issues in HIV pathogenesis related to clinical care
- Formulate appropriate management strategies for HIV and hepatitis B virus coinfection
- Describe the incidence, diagnosis, and management of bacterial infections in HIV-infected patients
- Discuss the implications of universal opt-out HIV testing on current treatment models and clinic structure
CME Credit
The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The International AIDS Society–USA designates this educational activity for a maximum of 6
AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.
Intended Audience
This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.
Course Faculty
Chairs
Gerald H. Friedland, MD
Course Chair
Professor of Medicine, Epidemiology,
and Public Health
Yale University School of Medicine
Director, AIDS Care Program
Yale-New Haven Hospital
New Haven, Connecticut
Paul A. Volberding, MD
Course Vice-Chair
Chair, Board of Directors
International AIDS Society–USA
Marvin Sleisenger Professor of Medicine
Vice-Chair, Department of Medicine
University of California San Francisco
Chief of Medical Service
San Francisco Veterans
Affairs Medical Center
San Francisco, California
Speakers
Judith A. Aberg, MD
Associate Professor of Medicine
New York University
Director of HIV Services
Bellevue Hospital Center
Principal Investigator
AIDS Clinical Trials Unit
New York, New York
John G. Bartlett, MD
Professor of Medicine
Founder and Director of HIV Care Service
The Johns Hopkins University
School of Medicine
Baltimore, Maryland
Ruth E. Berggren, MD
Associate Professor of Clinical Medicine
The University of Texas Health Science
Center at San Antonio
San Antonio, Texas
Joseph J. Eron, Jr, MD
Professor of Medicine
The University of North Carolina
at Chapel Hill
Principal Investigator
AIDS Clinical Trials Unit
Chapel Hill, North Carolina
Roy M. Gulick, MD, MPH
Member, Board of Directors
International AIDS Society–USA
Associate Professor of Medicine
Division of International Medicine and Infectious Diseases
Director of Cornell HIV Clinical Trials Unit
Weill Medical College of Cornell University
New York, New York
Kenneth H. Mayer, MD
Professor of Medicine and
Community Health
Director, The Brown AIDS Program
Brown University-The Miriam Hospital
Providence, Rhode Island
Paul E. Sax, MD
Associate Professor of Medicine
Harvard Medical School
Clinical Director
Division of Infectious Disease
Brigham and Women’s Hospital
Boston, Massachusetts
Bruce D. Walker, MD
Professor of Medicine
Director of the Division of AIDS
Harvard Medical School
Director, Partners AIDS Research Center
Massachusetts General Hospital
Boston, Massachusetts
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson received research support from or served as a consultant to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, and Pfizer. She had stock options for Monogram Biosciences and Vertex. (Updated 03/21/07)
Judith S. Currier, MD
Dr Currier received grants and research support from and served as a consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, and Tibotec. (Updated 03/12/07)
Carlos del Rio, MD
Dr del Rio received grants and research support from GlaxoSmithKline, Merck, and Pfizer. He served as a consultant or was on the speakers’ bureau of Abbott, Merck, and Roche. (Updated 10/09/06)
Joel E. Gallant, MD, MPH
Dr Gallant received grants and research support from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram Sciences, Panacos, Pfizer, Schering Plough, Tibotec, and Vertex. (Updated 10/09/07)
Roy M. Gulick, MD, MPH
Dr Gulick received research grants from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, Roche-Trimeris, Schering, Tibotec, and Virco. (Updated 03/05/07)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 03/22/07)
Douglas D. Richman, MD
Dr Richman served as a consultant to Achillion, Anadys, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Idinex, Merck, Monogram, Pfizer, Roche, and Tibotec. (Updated 10/09/06)
Michael S. Saag, MD
Dr Saag received grants and research support from Achillion Pharmaceuticals, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Progenics, Roche, Serono, Tibotec, Trimeris, and Vertex. He served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex. (Updated 03/22/07)
Robert T. Schooley, MD
Dr Schooley received and research support and honoraria from or served as a consultant to Abbott, Anadys, Anormed, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Roche, Schering-Plough, Tanox, Tibotec and Vertex. (05/16/07)
Paul A. Volberding, MD
Dr Volberding served on the advisory boards for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering. He received honoraria for speaking from Bristol-Myers Squibb, Gilead, and Vertex. He had stock options for Immune Response Corporation. (Updated 01/22/07)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr Aberg received honorarium from Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, and Roche. She served on advisory board for Abbott, Bristol-Myers Squibb, Gilead, and GlaxoSmithKline. She received research support from Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec.
Dr Bartlett served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, and Pfizer. He received grants and research support and honorarium for speaking from Abbott and Gilead.
Dr Berggren had no relevant financial affiliations to disclose.
Dr Eron received grants and research support from GlaxoSmithKline, Merck, and Panacos. He served as a consultant to Abbott, Bristol-Myers Squibb Virology, GlaxoSmithKline, Merck, Tibotec, and Trimeris. He was also on the speaker’s bureau of Gilead, Roche, and Tibotec. He received fees for written enduring materials, Internet activities, and/or audio activities from Bristol-Myers Squibb.
Dr Friedland had no relevant financial affiliations to disclose.
Dr Gulick received research grants from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, Roche-Trimeris, Schering, Tibotec, and Virco.
Dr Mayer received grants and research support from Gilead. He received honoraria from or was on the speaker’s bureau of Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, and Pfizer. He received fees for written enduring materials, Internet activities, and/or audio activities from Health Matters Communications and Medscape.
Dr Sax received grants and research support from Bristol-Myers Squibb, Merck, and Pfizer, and honoraria for teaching from Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Tibotec, and Virco. He served as a consultant to Abbott, Bristol-Myers Squibb, Gilead, and GlaxoSmithKline.
Dr Volberding served on the advisory boards for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering. He received honorarium for speaking from Bristol-Myers Squibb, Gilead, and Vertex. He had stock options for Immune Response Corporation.
Dr Walker served as a consultant to Bristol-Myers Squibb, GlobeImmune, and Merck.
IAS–USA CME Staff
Ms Jacobsen has no relevant financial affiliations to disclose.
Ms Wilson has no relevant financial affiliations to disclose.
Grant Support
This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.
Funding for the live activity, upon which this activity was based came from the following commercial companies:
Substantial Grants from:
Bristol-Myers Squibb
Tibotec Therapeutics
Abbott Laboratories
Gilead Sciences
Pfizer Global Pharmaceuticals
Roche Pharmaceuticals
Generous Grants from:
GlaxoSmithKline
Additional grant support for this course:
Merck and Co., Inc.
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2007@iasusa.org
